Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes

Archive ouverte

Carrieri, Patrizia | Mourad, Abbas | Marcellin, Fabienne | Trylesinski, Aldo | Calleja, José, Luis | Protopopescu, Camelia | Lazarus, Jeffrey, V

Edité par CCSD ; Wiley-Blackwell -

International audience. Background & Aims: Though lifestyle interventions can reverse disease progression in people with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/ NASH), unawareness about disease severity might compromise behavioural changes. Data from this first international cross-sectional survey of individuals with NAFLD/ NASH were used to identify correlates of both unawareness about fibrosis stage and its association with adherence to lifestyle adjustments. Methods: Adults with NAFLD/NASH registered on the platform Carenity were invited to participate in an online 20-min, six-section survey in Canada, France, Germany, Italy, Spain and the United Kingdom to describe their experience with NAFLD/NASH and its care (N = 1411). Weighted binary and multinomial logistic regressions were performed to estimate the effect of explanatory variables on unawareness of fibrosis stage and poor adherence to lifestyle changes respectively. Results: In the study group, 15.5% had obesity and 59.2% did not know their fibrosis stage. After multiple adjustments, individuals with a body mass index (BMI) ≥35 were over twice as likely to not know their fibrosis stage. People with a BMI >30 had a threefold higher risk of having poor adherence to lifestyle changes. Unawareness about fibrosis stage was also significantly associated with poor adherence to lifestyle adjustments. Conclusions: As fibrosis stage is becoming the main predictor of NAFLD progression, improving patient-provider communication-especially for people with obesityabout liver fibrosis stage, its associated risks and how to mitigate them, is needed. Training for healthcare professionals and promoting patient educational programmes to support behaviour changes should also be included in the liver health agenda.

Suggestions

Du même auteur

Author response: Improving patient‐provider communication by reducing stigma associated with liver disease

Archive ouverte | Carrieri, Patrizia | CCSD

International audience. No abstract available

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)

Archive ouverte | Marcellin, Fabienne | CCSD

International audience. Background & aims: Patient-reported outcomes (PROs) are poorly documented for patients with chronic hepatitis C on direct-acting antiviral (DAA) treatment in low-to-middle-income countries. W...

Hepatitis C treatment: Temporal and regional variations in the percentage of first-time prescriptions of direct-acting antivirals by general practitioners and associated factors, ANRS FANTASIO 2 project, mainland France, 2019–2022. Traitement de l’hépatite C : variations temporelles et régionales de la part des primo-prescriptions d’antiviraux à action directe par les médecins généralistes et facteurs associés, projet ANRS Fantasio 2, France hexagonale, 2019-2022

Archive ouverte | Marcellin, Fabienne | CCSD

International audience. Introduction – In May 2019, first prescription of direct-acting antivirals (DAA) for treatment of hepatitis C, initially reserved for specialists practicing in hospitals, was extended to all ...

Chargement des enrichissements...